Stories

At Ipsen, our heritage in neuroscience has always been about more than advancing science – it is about transforming lives. Despite advances in care and numerous initiatives to prevent stroke, cases continue to rise over recent decades.

Elisabetta Leo is moving science forward at the heart of early development. This involves progressing nonclinical data and novel molecules in oncology, from bench to bedside.

Philippe Lopes-Fernandes, EVP & Chief Business Officer, shares how Ipsen’s tenacious approach to dealmaking is transforming breakthrough science into global impact—solidly.

Developing an antibody-drug conjugate (ADC) is a technical challenge. Across Ipsen’s work in ADCs Will Olughu leads a team driving the chemistry, manufacturing, and controls (CMC) effort to bring this complex science into reality.

It is a pivotal moment in Ipsen’s oncology journey, advancing our clinical-stage pipeline with bold science and a clear purpose – to bring meaningful innovation to the patients who need it most, transforming what patients and healthcare systems can expect from cancer treatment.